StemCell Institute
TSE:7096
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
751
1 527
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| JP |
|
StemCell Institute
TSE:7096
|
8.3B JPY |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
93.3B USD |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
72.3B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
60.5B EUR |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
26.4B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.4B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
20.3B USD |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
14B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR |
Loading...
|
|
| AU |
|
Sonic Healthcare Ltd
ASX:SHL
|
11B AUD |
Loading...
|
Market Distribution
| Min | -125 500% |
| 30th Percentile | 4.2% |
| Median | 7% |
| 70th Percentile | 10.6% |
| Max | 9 743.7% |
Other Profitability Ratios
StemCell Institute
Glance View
StemCell Institute KK engages in stem cell banking business. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 82 full-time employees. The company went IPO on 2021-06-25. The firm operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo. The company will be stored at its own cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for StemCell Institute is 10.4%, which is below its 3-year median of 15.2%.
Over the last 3 years, StemCell Institute’s Operating Margin has decreased from 14.4% to 10.4%. During this period, it reached a low of 10.4% on Sep 30, 2025 and a high of 17.4% on Jun 30, 2024.